Lineage Cell Therapeutics enters new ATM facility with B. Riley; FDA delays OPC1 study start

Lineage Cell Therapeutics, Inc.

Entered Sales Agreement with B. Riley Securities to sell up to $6.7M in common shares via at-the-market offering; 3% commission.
Terminated prior ATM with Cantor Fitzgerald; prior program sold approximately $6.66M in shares.
FDA review of OPC1 IND for spinal cord injury ongoing; requested not to initiate DOSED study until feedback expected by April 26, 2024.
Initial FDA clinical information request resolved; company aims to open first DOSED study site in Q2 2024.
No change to previously guided timeline for study initiation; no additional activities required to address FDA request.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lineage Cell Therapeutics, Inc. entered into Sales Agreement with B. Riley Securities, Inc. (effective 2024-03-22).

Action: entry
Agreement: atm program
Counterparty: B. Riley Securities, Inc.
Effective: 2024-03-22

Exact text from the filing

on March 22, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”), entered into a sales agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”), under which the Company may offer and sell its common shares from time to time through the Sales Agent as the Company’s sales agent.

View on SEC.gov

545 material agreements filed in the last 30 days. Browse all material agreements →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-035365

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.